...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Haematology >Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
【24h】

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry

机译：常规临床实践中的Romiplosim治疗原发性免疫血小板减少症（ITP）：英国ITP注册机构的回顾性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Romiplostim is a thrombopoietin‐mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice. Methods This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6?months before romiplostim initiation through follow‐up. Results Of 1440 patients in the UKITP Registry, 118 adults with primary ITP were eligible. Before romiplostim, 22% had splenectomy, 12% received platelet transfusion, 97% received?≥?1 different ITP medication and 77% received?≥?3. Most patients (73%) initiated romiplostim?≥?1?year after ITP diagnosis (chronic phase). The mean duration of romiplostim treatment was 5.7 (SE 0.9) months, and the median was 1.4?months (IQR: 0.2, 6.5). Mean platelet count before romiplostim was 38?×?10 9 /L, rising to 103?×?10 9 /L within 1?month, and remaining 50‐150?×?10 9 /L through up to 3?years of follow‐up. After romiplostim, 4% of patients had splenectomy, 6% received platelet transfusion, and 57% received just one ITP medication other than romiplostim. Conclusion The study provides valuable insights into the real‐world use of romiplostim in primary ITP in routine practice and highlighted the timing of romiplostim initiation at different ITP disease phases.
机译：摘要背景romiplostim是成人难治性慢性免疫血小板减少症（ITP）的血小板模拟癫痫患者。我们旨在描述英国临床实践中接受Romiplosim，血小板计数和Romiplostim使用的ITP患者。方法是，这是在2009年10月和2015年1月期间收到的Hyitp注册处的患者的回顾性队列研究，包括2015年1月至2015年1月，包括最多6个月的数据，并通过随访开始前6个月。结果1440名患者在UKITP注册处，118名主要ITP的成年人有资格。在romiplostim，22％的脾切除术，12％接受血小板输血，97％接受？≥？1种不同的ITP药物和77％接受？≥？3。大多数患者（73％）启动了Romiplosim？≥？1？ITP诊断后的一年（慢性阶段）。 romiplosim治疗的平均持续时间为5.7（SE 0.9）个月，中位数为1.4？月份（IQR：0.2,6.5）。在romiplosimim之前的平均血小板计数为38？×10 9 / l，上升至103？×10 9 / l在1？个月内，剩下50-150？×10 9 / l到达3？多年的关注-向上。在Romiplostim之后，4％的患者患有脾切除，6％接受血小板输注，57％只接受了romiplosim以外的ITP药物。结论该研究提供了有价值的见解，对常规实践中的主要ITP中的Romiplostim在原发性ITP中使用并突出了不同ITP疾病阶段的romiplosim发育的时序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号